FindTrial
Sign In

Use of fibroscan as a safe diagnostic tool on women diagnosed to have type 1 diabetes in 1st trimester of pregnancy for early diagnosis of liver diseases

Assessment of liver stiffness by fibroscan in pregnant women of 1st trimester with pre gestational diabetes mellitus without known hepatic pathology for early diagnosis of liver disorders - Nil

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/12/098391
Enrollment
96
Registered
2025-12-03
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O099- Supervision of high risk pregnancy, unspecified

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

ICMR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All pregnant women in first trimester with pre gestational diabetes mellitus

Exclusion criteria

Exclusion criteria: Patients with known hepatic pathology like chronic liver diseases, liver cirrhosis, auto immune hepatitis, hepatocellular carcinoma etc.

Design outcomes

Primary

MeasureTime frame
Observation of fibroscan results of pregnant women with pre gestational diabetes mellitus(PGDM) without known hepatic pathology in the first trimester of pregnancy for early diagnosis o liver diseases and prompt referral.Timepoint: 1 year—

Secondary

MeasureTime frame
Fetal and maternal outcomes followup and reduction of maternal and perinatal mortality and morbidity due to liver disorders in pregnancy.Timepoint: 1 year—

Countries

India

Contacts

Public ContactAadrita Bishnu

Jawaharlal Nehru Medical College

aadrita280505@gmail.com7002801460

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026